Mar­tin Shkre­li made a name for him­self for goug­ing the price of Dara­prim by 4,000%, say­ing he should’ve raised it even high­er, and then fac­ing an ex­pect­ed back­lash from both Con­gress and the courts over his greed. The re­sult: a life­time ban from the phar­ma in­dus­try and a $65 mil­lion fine.

Now, the Fed­er­al Trade Com­mis­sion said to­day in a court fil­ing in the south­ern dis­trict of New York that Shkre­li is vi­o­lat­ing that ban by fail­ing to pay his fine and by form­ing a new com­pa­ny, called “Drug­like, Inc.,” which claims to be in­volved in “ear­ly stage drug dis­cov­ery.”

The re­sponse from the FTC fol­lows a fed­er­al judge in New York’s de­ci­sion in Feb­ru­ary to up­hold the life­time in­dus­try ban placed on Shkre­li af­ter the ex-“Phar­ma Bro” ap­pealed the de­ci­sion. That or­der re­quires Shkre­li to pro­vide com­pli­ance re­ports and oth­er doc­u­ments to show that he’s ad­her­ing to this life­time ban.

Shkre­li and his lawyers large­ly ob­ject­ed to the scope of the ban, ar­gu­ing it was too vague and bur­den­some. The court, how­ev­er, es­sen­tial­ly pre­vent­ed Shkre­li from mak­ing any pub­lic state­ments about the phar­ma in­dus­try at all.

But the FTC says he still isn’t in com­pli­ance with that or­der and the com­mis­sion is ask­ing the court to now or­der him to sub­mit a com­plete com­pli­ance re­port with­in 10 days of the court’s de­ci­sion, pro­vide the FTC with ac­cess to all rel­e­vant doc­u­ments or copies of all rel­e­vant doc­u­ments pre­vi­ous­ly re­quest­ed by the FTC, and to sit for an in­ter­view with­in three weeks.

Shkre­li down­played the fil­ing in his newslet­ter on Sun­day:

My lawyers and I missed a dead­line to file a rou­tine up­date with the FTC and sched­ule a meet­ing. That will be done. I’m not in con­tempt and won’t be ‘in trou­ble’ over this. Mea cul­pa. It turns out some peo­ple on my team were sick dur­ing the re­sponse pe­ri­od and there was some tele­phone tag. To­tal non-event, but don’t tell that to the me­dia who in­sists this is some­how ‘news’.

Ed­i­tor’s note: Ar­ti­cle up­dat­ed with Shkre­li’s com­ment.

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

We now know where Roche’s ex-pharma chief Bill Anderson is going.

German pharma giant Bayer announced Wednesday that Anderson will be taking on the role as CEO, less than six weeks after Anderson stepped down from his perch at Roche as head of the group’s pharmaceutical division.

Roche announced back in December that Anderson would depart on Dec. 31 to “pursue opportunities outside of Roche.” His replacement, Genentech vet and Roche’s current head of global product strategy, Teresa Graham, will start her role in March.

The DC Circuit Court has struck a blow against the pharmaceutical lobbying group PhRMA and other plaintiffs’ attempt to stop states from importing drugs from Canada.

Joined alongside public health group Partnership for Safe Medicines and advocacy group Council for Affordable Health Coverage, PhRMA was rebuffed by Judge Timothy Kelly on Monday, who dismissed the civil suit due to a lack of standing.